ask colleagues join paying special tribute major general john harris, retirement ohio national guard.
behalf citizens ohio, wish general harris best assumes new position director ohio department veterans affairs.
along entire ohio delegation thank forty- four years service ohio nation.- meeks.., rise today recognize importance orphan drug act driving rare disease therapy clinical research district university iowa.
physician, legislator, member rare disease congressional caucus, seen firsthand life- changing impact medical innovation patients battling rare diseases.
iowas first congressional district home clinical trials several rare diseases lack food drug administration( fda)- approved therapy, including becker muscular dystrophy, gaucher disease type, limb girdle muscular dystrophy.
patients, millions americans suffering rare diseases, scientific advancements represent medical progress-- offer hope none previously existed.
hope would possible without orphan drug act, served foundation rare disease drug development four decades.
orphan drug acts critical incentive orphan drug exclusivity, seven- year period market exclusivity.
incentive ensures innovators willing take extraordinary risk developing first-- class treatment complex condition affecting small patient population appropriately rewarded.
many rare diseases, first fda- approved treatment lifeline.
therapies often require years research, billions investment, considerable perseverance bring medicines patients.
without strong reliable exclusivity framework, treatments simply would exist.
intended orphan exclusivity serve`` marketplace- oriented solution provide incentives private enterprise develop orphan drugs.
fda established regulations aimed protect critical economic incentive also encouraging continued innovation rare disease allowing follow- product drug use break orphan exclusivity demonstrates greater efficacy, greater safety,`` major contribution patient care relative original orphan drug.
codified regulations 2017.
long recognized`` major contribution care prong`` clinical superiority standard meant high bar.
intend minor modifications changes dosing frequency formulation erode exclusivity protections first innovator drug unless modifications result significant clinical benefit treating underlying conditions.
allow marginal improvements rather true clinical advancements justify breaking orphan exclusivity, undermine incentive encourages companies develop first-- class therapies first place.
fda clear precedent maintaining high bar clinical superiority determinations.
lower bar breaking orphan exclusivity, especially`` major contribution patient care, undermine future rare disease drug development.
lowering bar deter investment first-- class therapies reducing certainty companies able benefit exclusivity protections intended.
lowering bar create regulatory uncertainty, leading litigation, market instability, hesitation investors fund rare disease innovation.
lowering bar set dangerous precedent copycat products modifications, encouraging incremental changes rather bold scientific advancements.
lowering bar hurt patients, delaying discouraging development first- ever therapy nearly 10, 000 rare diseases still lack fda- approved treatment.
physician, know true medical breakthroughs require bold investment, sustained commitment, regulatory certainty.
legislator, committed preserving integrity orphan drug act ensuring continues drive life- changing treatments patients.
fda must apply law intended allow minor modifications erode exclusivity protections serve foundation rare disease innovation.
today, calling fellow members rare disease congressional caucus stand together protect value incentives established orphan drug act.